Description

Nevanak (nepafenac) Eye Drops Suspension 1 mg/ml. 5 ml Vial

Ingredients

Nevanak contains nepafenac as the active ingredient. Other ingredients include benzalkonium chloride, boric acid, edetate disodium, sodium chloride, and purified water.

Dosage

The recommended dosage is one drop in the affected eye(s) three times daily, beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 2 weeks of the postoperative period.

Indications

Nevanak is indicated for the treatment of pain and inflammation associated with cataract surgery.

Contraindications

Do not use Nevanak if you are allergic to nepafenac or any other ingredients in the product. It is also contraindicated in patients with a history of asthma, urticaria, or other allergic reactions after taking aspirin or other NSAIDs.

Directions

Before using Nevanak, ensure hands are clean. Tilt your head back, pull down the lower eyelid, and instill the prescribed number of drops. Close your eye for 2 minutes, avoiding blinking or squeezing the eye.

Scientific Evidence

Studies have shown that nepafenac, the active ingredient in Nevanak, inhibits the enzyme cyclooxygenase (COX), reducing inflammation and pain. Clinical trials have demonstrated its efficacy in reducing postoperative inflammation and improving patient comfort after cataract surgery.

Additional Information

It is important to follow the prescribed dosage and duration of treatment with Nevanak to achieve optimal results. Contact your healthcare provider if you experience any side effects or have concerns about the medication.

Pharmacological Effects: Nepafenac is a prodrug that is rapidly metabolized to amfenac, a potent NSAID. It exerts its pharmacological effects by inhibiting the production of inflammatory mediators such as prostaglandins, thereby reducing inflammation and pain.

Clinical Trials: A randomized, double-blind study by Miyake et al. (2018) compared the efficacy of nepafenac eye drops with placebo in patients undergoing cataract surgery. The results showed a significant reduction in postoperative inflammation and pain in the nepafenac group, highlighting its clinical benefits.